Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

Completed

Conditions studied: PDAC - Pancreatic Ductal Adenocarcinoma

In brief

Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinical need. The EXELiM study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to accurately identify PDAC patients at high risk of occult liver metastasis before surgery. By integrating machine learning with multi-institutional plasma exosome profiling, this study seeks to enable biology-driven patient stratification and guide treatment sequencing toward precision oncology.

Key facts

Study ID

NCT07224802

Run by

City of Hope Medical Center

People needed

372

Starts

2024-06-21

Expected to finish

2026-02-18

Last updated by the study team

2026-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed pancreatic ductal adenocarcinoma (PDAC)
• Undergoing curative-intent pancreatectomy
• Availability of preoperative plasma samples
• Complete clinical and follow-up data
• Written informed consent obtained

You may not qualify if…

• Synchronous or secondary malignancies
• Non-adenocarcinoma histology
• Lack of informed consent
• Incomplete plasma sample data

Where it is running

• City of Hope Medical Center — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.